| 產(chǎn)品名稱 |
Vaccinia virus ts mutant |
| 商品貨號(hào) |
B163246 |
| Classification |
Poxviridae, Orthopoxvirus |
| Agent |
Vaccinia virus ts mutant |
| Strain |
IHD-W Dts19 |
| Applications |
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E11, a 129 amino acid core protein that is synthesized late during infection. |
| Biosafety Level |
2 BSL 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation |
This conditional lethal mutant, originally designated plaque isolate no. 2096, was isolated from the IHD-W strain of Vaccinia by S. Dale after mutagenesis with nitrosoguanidine (Dales, et al, 1978). The non-permissive incubation temperature is 39.5 C. This mutant was assigned to Dales EM category B, indicating that it induces foci of a fibrous viroplasmic matrix substance without membranes in infected cells. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E11, a 129 amino acid core protein that is synthesized late during infection.
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses |
| Product Format |
frozen |
| Storage Conditions |
-70°C or colder |
| Comments |
This conditional lethal mutant, originally designated plaque isolate no. 2096, was isolated from the IHD-W strain of Vaccinia by S. Dale after mutagenesis with nitrosoguanidine (Dales, et al, 1978). The non-permissive incubation temperature is 39.5 C. This mutant was assigned to Dales EM category B, indicating that it induces foci of a fibrous viroplasmic matrix substance without membranes in infected cells. The mutation was assigned by complementation analysis (Lackner, et al, 2003) to vaccinia map location E11, a 129 amino acid core protein that is synthesized late during infection.
Vaccination is recommended for laboratory staff manipulating vaccinia, monkeypox, and cowpox viruses |
| Effect on Host |
Cytopathic effects in culture include enlargement and rounding of cells, followed by death and sloughing CPE: enlargement, plaques with rounding and eventual sloughing |
| Growth Medium |
ATCC® Medium 30-2003: Eagle's Minimum Essential Medium (EMEM)
Fetal Bovine Serum
|
| Recommended Host |
Production Host: BSC-40 (ATCC CRL-2761) Recommended Host: BSC-40 (ATCC CRL-2761) Alternate Host(s): MRC-5, BS-C-1, HeLa, LLC-MK2 |
| Growth Conditions |
Duration: 1-3 days at 31 C with 5% CO2 |
| Name of Depositor |
S Dales, R. Condit |
| References |
Dales S, et al. Biogenesis of vaccinia: isolation of conditional lethal mutants and electron microscopic characterization of their phenotypically expressed defects. Virology 84: 403-428, 1978. PubMed: 622807
Condit RC, et al. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 128: 429-443, 1983. PubMed: 6577746
Lackner CA, et al. Complementation analysis of the Dales collection of vaccinia virus temperature-sensitive mutants. Virology 305: 240-259, 2003. PubMed: 12573570
Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online.
|
